- Products Pipeline
- Clinical cases
Cellular medicines Pipeline
Several stem cell medicines we developed have entered the stage of clinical research:
Umbilical cord mesenchymal stem cells injection for graft-versus-host disease, liver cirrhosis and myocardial ischemia has entered Phase II clinical research.
hUC-MSC injection High-efficiency placenta derived mesenchymal stem cells injection for patients with type 2 diabetes, critical limb ischemia and aplastic anemia has also entered Phase II clinical stage.
Placenta EPC Injection, is in the preclinical stage.